Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits

Parrilha, Letícia Rodrigues; Nai, Gisele Alborghetti; Giuffrida, Rogério; Barbero, Rafael Cabral; Padovani, Leticia Dias Fabris; Pereira, Ricardo Henrique Zaquir; Silva, Danielle Alves; Silva, Mariele Catherine Alves; Diniz, Miriely Stein; Andrade, Silvia Franco

doi:10.5935/0004-2749.20150078

Cited by 10 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An animal study conducted in 2015 compared the efficacy of 1% cyclosporine eye drops in olive oil or linseed oil for the treatment of experimentally-induced keratoconjunctivitis sicca (KCS) rabbits. The results support that cyclosporine diluted in both olive oil or linseed oil was effective in the treatment of KCS, although it had better efficacy in linseed oil [143]. These findings may give birth to the creation of novel topical ophthalmic formulations in future.…”

Section: Cyclosporine Asupporting

confidence: 59%

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Kuo

Lin

Chien

et al. 2019

JCM

View full text Add to dashboard Cite

Dry eye disease (DED) has become common on a global scale in recent years. There is a wide prevalence of DED in different countries based on various ethnicities and environment. DED is a multifactorial ocular disorder. In addition to advanced age and gender, such factors as living at high altitude, smoking, pterygium, prolonged use of consumer electronics or overingesting of caffeine or multivitamins are considered to be the major risk factors of DED. We report the DED epidemiology in Taiwan firstly in this article. According to the pathophysiological factors and changes inthe composition of the tear film in DED, it can be categorized into several subtypes, including lipid anomaly dry eye, aqueous tear deficiency, allergic and toxic dry eye among others. Each subtype has its own cause and disease management; therefore, it is important for ophthalmologists to identify the type through literature review and investigation. The management of DED, relies not only on traditional medications such as artificial tears, gels and ointments, but also newer treatment options such as acupuncture, SYL1001, and nanomedicine therapy. We also conducted a comprehensive literature review including common subtypes and treatment of DED. Clearly, more clinical trials are needed to assess the efficacy and safety of the various treatments and common subtypes of DED.

show abstract

Section: Cyclosporine Asupporting

confidence: 59%

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Kuo

Lin

Chien

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…In this case, the potential synergistic effect of vitamin E could be due to its anti-inflammatory properties. A previously reported study in rabbits demonstrated that vitamin E could be used effectively as a diffusion barrier for pirfenidone-loaded contact lenses to treat inflammation after alkali burns (Parrilha et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Vitamin E as a Safe and Effective Vehicle for 1% Cyclosporine Eye Drops to Treat Chronic Non-Ulcerative Keratopathies in Dogs and Cats

2022

Int J Vet Sci

View full text Add to dashboard Cite

To evaluate the efficacy of topical cyclosporine A (CsA) diluted in vitamin E (CsA-E) to treat keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK) in dogs and proliferative eosinophilic keratitis (PEK) in cats. In addition, we also aimed to assess the safety and tolerability of topical CsA-E for dogs and cats. A total of 146 client-owned animals with chronic keratopathies: 96 dogs with KCS, 27 with CSK, and 23 cats with PEK were included in the study. All animals underwent a complete ophthalmic examination at the Visionvet Eye Clinic (Bologna, Italy). Eligible animals received a drop of CsA-E from one to three times daily depending on the severity of the lesions and the response to treatment. We analyzed the evolution of several clinical treatment responses (CTR) parameters at baseline and at three and six-month follow-up. All CTR parameters improved significantly in KCS and CSK dogs and PEK cats after topical CsA-E treatment at three and six-month follow-up, except for those symptoms barely present in our sample at baseline. No systemic adverse events were detected, but two dogs and one cat showed conjunctival hyperemia and blepharospasm after topical CsA-E treatment. Topical CsA-E was established as an effective treatment for KCS and CSK in dogs and PEK in cats. Vitamin E was deemed safe and tolerable for its topical use in animals and could be considered an adequate alternative to other oil-based solvents when considering CsA ophthalmic preparations.

show abstract

“…Inflammatory and fibrosis indices were evaluated as previously described. 22 The criteria for inflammation and fibrosis scoring based on H&E staining results were as follows: 0, no symptoms; 1, mild symptoms; 2, moderate symptoms; and 3, severe symptoms.…”

Section: Methodsmentioning

confidence: 99%

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models

Baek

Sung

Choi

et al. 2021

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose Dry eye disease (DED) is a multifactorial disorder of the tears and ocular surface accompanied by ocular discomfort, visual disturbance, tear film instability, and ocular surface inflammation. In the present study, we evaluated the efficacy of the tyrosine kinase inhibitor imatinib mesylate for the treatment of DED. Methods Experimental models of DED were generated in Sprague Dawley rats using a combination of benzalkonium chloride (BAC) with atropine sulfate and in New Zealand White rabbits using BAC. The animals were treated twice daily with eye drops of vehicle, imatinib (0.01%–0.3%), or a positive control (Restasis). The improvement in DED due to imatinib was assessed by staining with fluorescein, lissamine green, impression cytology, and histological analysis. In addition, immunofluorescence staining was performed at the end of the study to evaluate the inflammatory response in the ocular surface. Results Topical application of imatinib significantly reduced ocular surface damage compared with vehicle-treated animals. Imatinib restored the morphology and structure of the conjunctival epithelium and reduced the recruitment of immune cells in the corneal epithelium. Furthermore, imatinib significantly reduced the impression cytology score, thus demonstrating that imatinib prevents the loss of goblet cells in DED animal models. The therapeutic efficacy of imatinib was similar to or better than that of cyclosporine treatment. Conclusions In this study, we provide an animal in vivo proof of concept of the therapeutic potential of imatinib for the treatment of DED. Translational Relevance With this study we show the possibility of developing imatinib as a new ophthalmic drop to treat DED.

show abstract

Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits

Cited by 10 publications

References 22 publications

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Vitamin E as a Safe and Effective Vehicle for 1% Cyclosporine Eye Drops to Treat Chronic Non-Ulcerative Keratopathies in Dogs and Cats

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models

Contact Info

Product

Resources

About